BeOne Medicines AG - 예탁증서(보통주)
US ˙ NasdaqGS ˙ US07725L1026

SecurityONC / BeOne Medicines AG - Depositary Receipt (Common Stock)
InstitutionRYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity
Latest Disclosed Ownership754 shares
Latest Disclosed Value $ 182,520
RYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity reports 10.24% decrease in ownership of ONC / BeOne Medicines AG - Depositary Receipt (Common Stock)

On August 27, 2025 - RYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity filed a NPORT-P form disclosing ownership of 754 shares of BeOne Medicines AG - Depositary Receipt (Common Stock) (US:ONC) valued at $182,521 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 29, 2025 disclosing 840 shares of BeOne Medicines AG - Depositary Receipt (Common Stock). This represents a change in shares of -10.24% during the quarter. The current value of the position is $211,067 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-27 2025-06-30 NP BeOne Medicines EC US07725L1026 754 -86 -10.24 183 -20.18 2.0285
2025-05-29 2025-03-31 NP BeiGene EC US07725L1026 840 398 90.05 229 181.48 2.4287
2025-03-03 2024-12-31 NP BeiGene EC US07725L1026 442 442 82 0.8185
2022-02-28 2021-12-31 NP BeiGene EC US07725L1026 0 -703 -100.00 0 -100.00
2021-11-29 2021-09-30 NP BeiGene EC US07725L1026 703 -147 -17.29 255 -12.37 1.0728
2021-08-27 2021-06-30 NP BeiGene EC US07725L1026 850 34 4.17 292 2.46 1.2218
2021-05-27 2021-03-31 NP BeiGene EC US07725L1026 816 -397 -32.73 284 -9.27 1.2781
2021-03-01 2020-12-31 NP BeiGene EC US07725L1026 1,213 454 59.82 313 44.24 1.2764
2020-11-25 2020-09-30 NP BeiGene EC US07725L1026 759 -790 -51.00 217 -25.43 0.9074
2020-08-27 2020-06-30 NP BeiGene EC US07725L1026 1,549 154 11.04 292 70.18 1.1761
2020-06-01 2020-03-31 NP BeiGene EC US07725L1026 1,395 -89 -6.00 172 -30.20 1.0512
2020-03-02 2019-12-31 NP BeiGene EC US07725L1026 1,484 1,484 246 1.1386
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.